Ascend Advanced Therapies

We are thrilled to welcome two luminary #board members, John Chiminski as Chair of the Board and Karen Flynn, to continue our strategic growth. Read the full story here: https://lnkd.in/ePriQgTs

Did you know that #rarediseases affect 300 million people? On #RareDiseaseDay, and every day, it is an honor and a responsibility to be part of work aimed at making that number smaller. Learn more about the day and the movement behind it here: https://lnkd.in/gk6hbAF

"After years of broadening their capabilities to serve as one-stop-shops for diverse #biopharma needs, CDMOs are now embracing specialization to overcome the complexities of vast networks and the challenges of excelling in every area,” comments John Chiminski, former Chair and CEO of Catalent Pharma Solutions. We could not agree more with these sentiments in a recent The Pharma Navigator article featuring industry experts on the topic of CDMO specialization. Our journey of offering highly specialized services that take the guesswork out of your process continues with ABL. Reach out to learn how this benefits your team at [email protected].

How do PLK inhibitors increase AAV production? In this recent paper, Mo Mandegar, Chris Reid, Kaylin Fisher, Francis Grafton, Francesca Ispaso, Joshua Tworig, Rupert Derler, Andreas, Schulze, Florian Sonntag, and Markus H?rer used high-throughput screening to identify #cell cycle modulators that enhance AAV production. They found that PLK1 inhibitors significantly increased AAV yields across various conditions by halting the cell cycle. These findings offer potential solutions for improving AAV production to meet high demands with cost-effective #manufacturing strategies. Read the full paper here: https://lnkd.in/eVKata7S

Do you need to know what is in your rAAV vector batch, but are not sure what sequencing #method to use? A recent paper by our Munich Technology Development Team guides you how to choose wisely. You're invited to read our recent publication in Molecular Therapy Methods & Clinical Development on how developers can benefit from faster turn-around times and lower rAAV sample consumption authored by Florian Dunker-Seidler, Kathrin Breunig, Magdalena Haubner, Florian Sonntag, Markus H?rer and Rebecca Feiner. https://lnkd.in/dxebX8XQ

Phacilitate #ATW25 is in full swing in #Dallas! We are already feeling inspired and ready to make 2025 a memorable year in #cellandgenetherapy. Say hello if you see these friendly faces in the #Innovation Zone or out on the floor, and have a great show! ?? ?? ??

Day one of Phacilitate #ATW25 is off to a great clip as we head into #networking time! Packed panels and positive sentiments are all around even if it is a little chilly in #Dallas. We are excited for the floor to open tomorrow where you can find us in the #Innovation Zone. Reach out in the app or DM us here to connect.

It's just around the corner now! We are getting ready to mosey on over to Dallas for Phacilitate #ATW25. Looking forward to seeing you there. Find Mike Stella, Scott Broughton, Karim Pirani and Erika DS Wachs in the #Innovation Zone, on the app or DM us here! ?? ?? ??

Howdy, partner! We hope to see you in Dallas next week for the flagship Phacilitate event, Advanced Therapies Week (#ATW25). 2025 is already on a roll for us, and the team is excited to head to the #Innovation Zone and connect. Find us in the app or DM us here to set time.

“Reducing the #manufacturing costs is one important goal in our field, but what is even more important for our clients is to shorten the time to market.” Last year, Melanie Langhauser PhD offered this savvy insight when chatting with a group of industry experts and Pharmaceutical Technology. Now as 2025 gets off to a quick start, we could not be more excited about what this year has in store or more committed to helping developers build the future of #advancedtherapies. https://lnkd.in/escXKhi9